The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing
Open accessAbstract
Oncolytic herpes simplex virus type 1 (HSV-1) vectors are promising therapeutic agents for cancer. Their efficacy depends on the extent of both intratumoral viral replication and induction of a host antitumor immune response. To enhance these properties while employing ample safeguards, two conditionally replicating HSV-1 vectors, termed G47Δ and R47Δ, have been constructed by deleting the α47 gene and the promoter region of US11 from γ34.5-deficient HSV-1 vectors, G207 and R3616, respectively. Because the α47 gene product is responsible for inhibiting the transporter associated with antigen presentation (TAP), its absence led to increased MHC class I expression in infected human cells. Moreover, some G47Δ-infected human melanoma cells exhibited enhanced stimulation of matched antitumor T cell activity. The deletion also places the late US11 gene under control of the immediate-early α47 promoter, which suppresses the reduced growth properties of γ34.5-deficient mutants. G47Δ and R47Δ showed enhanced viral growth in a variety of cell lines, leading to higher virus yields and enhanced cytopathic effect in tumor cells. G47Δ was significantly more efficacious in vivo than its parent G207 at inhibiting tumor growth in both immune-competent and immune-deficient animal models. Yet, when inoculated into the brains of HSV-1-sensitive A/J mice at 2 × 10 6 plaque forming units, G47Δ was as safe as G207. These results suggest that G47Δ may have enhanced antitumor activity in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Markert, J. M., Medlock, M. D., Rabkin, S. D., Gillespie, G. Y., Todo, T., Hunter, W. D., Palmer, C. A., Feigenbaum, F., Tornatore, C., Tufaro, F., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301205 · Cited by 976
Self-citationAttenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas
Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D., & Martuza, R. L. (1995) · Nature Medicine · doi:10.1038/nm0995-938 · Cited by 822
Self-citationHerpes simplex virus turns off the TAP to evade host immunity
Hill, A., Jugovic, P., York, L., Russ, G., Bennink, J., Yewdell, J., Ploegh, H., & Johnson, D. (1995) · Nature · doi:10.1038/375411a0 · Cited by 803
Herpes simplex virus turns off the TAP to evade host immunity
(1995) · Trends in Genetics · doi:10.1016/0168-9525(95)90181-7 · Cited by 736
Chou, J., Kern, E. R., Whitley, R. J., & Roizman, B. (1990) · Science · doi:10.1126/science.2173860 · Cited by 711
A viral inhibitor of peptide transporters for antigen presentation
Früh, K., Ahn, K., Djaballah, H., Sempé, P., van Endert, P. M., Tampé, R., Peterson, P. A., & Yang, Y. (1995) · Nature · doi:10.1038/375415a0 · Cited by 602
A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes
York, I. A., Roop, C., Andrews, D. W., Riddell, S. R., Graham, F. L., & Johnson, D. C. (1994) · Cell · doi:10.1016/0092-8674(94)90215-1 · Cited by 559
Chou, J., & Roizman, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.8.3266 · Cited by 393
Goldstein, D. J., & Weller, S. K. (1988) · Journal of Virology · doi:10.1128/jvi.62.1.196-205.1988 · Cited by 392
Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47.
Ahn, K., Meyer, T. H., Uebel, S., Sempé, P., Djaballah, H., Yang, Y., Peterson, P. A., Früh, K., & Tampé, R. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00689.x · Cited by 358
Robbins, P. F., El‐Gamil, M., Kawakami, Y., Stevens, E., Yannelli, J. R., & Rosenberg, S. A. (1994) · PubMed · Cited by 248
Wang, F., Bade, E., Kuniyoshi, C., Spears, L., Jeffery, G., Marty, V., Groshen, S. G., & Weber, J. S. (1999) · PubMed · Cited by 242
Specific phenotypic restoration of an attenuated virus by knockout of a host resistance gene
Leib, D. A., Machalek, M. A., Williams, B. R. G., Silverman, R. H., & Virgin, H. W. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100415697 · Cited by 230
Seliger, B. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)01052-9 · Cited by 215
Goldsmith, K., Chen, W., Johnson, D. C., & Hendricks, R. L. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.3.341 · Cited by 206
Chambers, R., Gillespie, G. Y., Soroceanu, L., Andreansky, S., Chatterjee, S., Chou, J., Roizman, B., & Whitley, R. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1411 · Cited by 192
Hunter, W. D., Martuza, R. L., Feigenbaum, F., Todo, T., Mineta, T., Yazaki, T., Toda, M., Newsome, J. T., Platenberg, R. C., Manz, H. J., et al. (1999) · Journal of Virology · doi:10.1128/jvi.73.8.6319-6326.1999 · Cited by 191
Self-citationA herpesvirus genetic element which affects translation in the absence of the viral GADD34 function.
Mohr, I., & Gluzman, Y. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00853.x · Cited by 157
Krisky, D., Marconi, P., Oligino, T., et al. (1998) · Gene Therapy · doi:10.1038/sj.gt.3300755 · Cited by 153
Andreansky, S. S., Soroceanu, L., Er, F., Chou, J., Markert, J. M., Gillespie, G. Y., Roizman, B., & Whitley, R. J. (1997) · PubMed · Cited by 148
He, B., Chou, J., Brandimarti, R., Mohr, I., Gluzman, Y., & Roizman, B. (1997) · Journal of Virology · doi:10.1128/jvi.71.8.6049-6054.1997 · Cited by 142
Attenuated, Replication-Competent Herpes Simplex Virus Type 1 Mutant G207: Safety Evaluation in Mice
Sundaresan, P., Hunter, W. D. G., Martuza, R. L., & Rabkin, S. D. (2000) · Journal of Virology · doi:10.1128/jvi.74.8.3832-3841.2000 · Cited by 140
Self-citationHerpes Simplex Virus Type 2 ICP47 Inhibits Human TAP but Not Mouse TAP
Tomazin, R., van Schoot, N. E. G., Goldsmith, K., Jugovic, P., Sempé, P., Früh, K., & Johnson, D. C. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2560-2563.1998 · Cited by 125
Cassady, K. A., Gross, M. S., & Roizman, B. (1998) · Journal of Virology · doi:10.1128/jvi.72.9.7005-7011.1998 · Cited by 123
Johnson, P. A., Wang, M. J., & Friedmann, T. (1994) · Journal of Virology · doi:10.1128/jvi.68.10.6347-6362.1994 · Cited by 123
Self-citationTAP expression provides a general method for improving the recognition of malignant cells in vivo
Alimonti, J., Zhang, Q.-J., Gabathuler, R., Reid, G. S. D., Chen, S. S., & Jefferies, W. A. (2000) · Nature Biotechnology · doi:10.1038/75373 · Cited by 121
Jennings, S. R., Rice, P. L., Kloszewski, E. D., Anderson, R., Thompson, D. L., & Tevethia, S. S. (1985) · Journal of Virology · doi:10.1128/jvi.56.3.757-766.1985 · Cited by 118
Transcriptional targeting of herpes simplex virus for cell-specific replication
Miyatake, S., Iyer, A., Martuza, R. L., et al. (1997) · Journal of Virology · doi:10.1128/jvi.71.7.5124-5132.1997 · Cited by 108
Self-citationJugovic, P., Hill, A. B., Tomazin, R., Ploegh, H. L., & Johnson, D. C. (1998) · Journal of Virology · doi:10.1128/jvi.72.6.5076-5084.1998 · Cited by 105
Todo, T., Martuza, R. L., Dallman, M. J., & Rabkin, S. D. (2001) · PubMed · Cited by 89
Self-citationMavromara-Nazos, P., Ackermann, M., & Roizman, B. (1986) · Journal of Virology · doi:10.1128/jvi.60.2.807-812.1986 · Cited by 61
Cited by
Exploring treatment options in cancer: tumor treatment strategies
Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01856-7 · Cited by 1,201
Liu, B. L., Robinson, M., Han, Z.-Q., Branston, R. H., English, C., Reay, P., McGrath, Y., Thomas, S. K., Thornton, M., Bullock, P., et al. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301885 · Cited by 803
Oncolytic virus therapy: A new era of cancer treatment at dawn
Fukuhara, H., Ino, Y., & Todo, T. (2016) · Cancer Science · doi:10.1111/cas.13027 · Cited by 774
Self-citationSaha, D., Martuza, R. L., & Rabkin, S. D. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.006 · Cited by 591
Self-citationIntratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial
Todo, T., Ito, H., Ino, Y., Ohtsu, H., Ota, Y., Shibahara, J., & Tanaka, M. (2022) · Nature Medicine · doi:10.1038/s41591-022-01897-x · Cited by 526
Self-citation
Metadata
- Authors
- Todo, T., Martuza, R. L., Rabkin, S. D., & Johnson, P. A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2001-05-15
- Volume
- 98
- Issue
- 11
- Pages
- 6396-6401
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2165652424
- Cited by
- 465
- References
- 31
- FWCI
- 4.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.